Safety of insulin analogs during pregnancy: a meta-analysis
The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
Objective The objective of this study was to assess the safety of four insulin analogs (aspart, lispro, glargine, and detemir) for the treatment of diabetes in pregnancy.Methods We searched Embase, Pubmed, and the Cochrane Central Register for Controlled Trials database through May 31, 2014. All articles were reviewed by two independent researchers, and if a discrepancy was noted, a third researcher was consulted. Results data were summarized by RevMan 5.2 software.Results Our search resulted in the retrieval and screening of 3519 studies. Of those, 24 studies met the eligibility criteria; the studies reported on a total of 3734 women with pre-gestational or gestational diabetes during pregnancy. The use of lispro was associated with lower rates of neonatal jaundice (RR = 0.63) and severe maternal hypoglycemia (RR = 0.33) than regular insulin. Lispro use was also associated with higher birth weight (WMD = 116.44) and an increased incidence of large for gestational age (LGA) births (RR = 1.42) compared with regular insulin. Rates of cesarean section and macrosomia were similar in pregnant women treated with aspart and regular insulin. Birth weights and rates of severe maternal hypoglycemia, respiratory dysfunction syndrome, and neonatal intensive care unit admission were similar after pregnant women were treated with glargine and NPH insulin. Rates of LGA, macrosomia, and neonatal hypoglycemia were similar after pregnant women were treated with detemir and NPH insulin.Conclusions Aspart, glargine, and detemir are safe treatment options for diabetes during pregnancy; these insulin analogs did not increase complications for the mothers or fetuses in our study. However, lispro was related to higher birth weight and increased rate of LGA in neonates. More high-quality randomized controlled trials are needed to clarify the best treatment options for diabetes during pregnancy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the rapid-acting insulin analogs aspart and lispro have acceptable safety and efficacy profiles in pregnancy.59,60”
From Gestational Diabetes Mellitus (2019) · cites this paper as [59]
Citations
Cites
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Kurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739 · cited 3×
“Aspart has a similar affinity for the IGF-1 receptor compared to regular insulin, but lispro has a higher affinity for the IGF-1 receptor [28].”
BackgroundSocioeconomic Disparities in Adverse Birth Outcomes
Blumenshine, P., Egerter, S., Barclay, C. J., Cubbin, C., & Braveman, P. A. (2010) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2010.05.012 · Cited by 688
Lawrence, J. M., Contreras, R., Chen, W., & Sacks, D. A. (2008) · Diabetes Care · doi:10.2337/dc07-2345 · Cited by 658
DeSisto, C. L., Kim, S. Y., & Sharma, A. J. (2014) · Preventing Chronic Disease · doi:10.5888/pcd11.130415 · Cited by 577
Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline
Blumer, I., Hadar, E., Hadden, D. R., Jovanovič, L., Mestman, J. H., Murad, M. H., & Yogev, Y. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2465 · Cited by 561
I., E., Valk, H. D., B., M., Braak, E. T., & G., V. (2002) · Diabetologia · doi:10.1007/s00125-002-0958-7 · Cited by 279
Hod, M., Damm, P., Kaaja, R., Visser, G. H. A., Dunne, F., Demidova, I., Hansen, A.-S. P., & Mersebach, H. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.08.005 · Cited by 176
Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling
Sciacca, L., Cassarino, M. F., Genua, M., Pandini, G., Moli, R. L., Squatrito, S., & Vigneri, R. (2010) · Diabetologia · doi:10.1007/s00125-010-1760-6 · Cited by 152
Transfer of Insulin Lispro Across the Human Placenta
Boskovic, R., Feig, D. S., Derewlany, L., Knie, B., Portnoi, G., & Koren, G. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1390 · Cited by 123
Safety of Insulin Glargine Use in Pregnancy: A Systematic Review and Meta-Analysis
Pollex, E., Moretti, M. E., Koren, G., & Feig, D. S. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p327 · Cited by 116
Insulin Glargine Safety in Pregnancy
Pollex, E. K., Feig, D. S., Lubetsky, A., Yip, P. M., & Koren, G. (2010) · Diabetes Care · doi:10.2337/dc09-1045 · Cited by 104 · cited 1×
“[35] demonstrated that glargine cannot cross the placenta to influence fetal growth.”
BackgroundHod, M., Mathiesen, E. R., Jovanovič, L., McCance, D. R., Ivanisevic, M., Durán-Garcia, S., Brøndsted, L., Nazeri, A., & Damm, P. (2014) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2013.799650 · Cited by 100
Use of insulin glargine during pregnancy: a case-control pilot study
Price, N., Bartlett, C., & Gillmer, M. (2007) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.01216.x · Cited by 93
Wilde, M. I., & McTavish, D. (1997) · Drugs · doi:10.2165/00003495-199754040-00006 · Cited by 79
Durnwald, C. P., & Landon, M. B. (2008) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050802022797 · Cited by 61
Lapolla, A., Dalfrà, M. G., Spezia, R., Anichini, R., Bonomo, M., Bruttomesso, D., Di Cianni, G., Franzetti, I., Galluzzo, A., Mello, G., et al. (2008) · Acta Diabetologica · doi:10.1007/s00592-008-0024-0 · Cited by 58
Negrato, C. A., Rafacho, A., Negrato, G., Teixeira, M. F., Araújo, C. A. R., Vieira, L., Silva, C. A., Date, S. K., Demarchi, A. C., & Gomes, M. B. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.03.015 · Cited by 55
Effect of Excess Gestational Weight Gain on Pregnancy Outcomes in Women With Type 1 Diabetes
Scifres, C. M., Feghali, M. N., Althouse, A. D., Caritis, S. N., & Catov, J. M. (2014) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000271 · Cited by 55
Use of insulin glargine during pregnancy
PÖYHÖNEN‐ALHO, M., RÖNNEMAA, T., SALTEVO, J., EKBLAD, U., & KAAJA, R. J. (2007) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1080/00016340701515282 · Cited by 52
(2004) · PubMed · Cited by 51
Callesen, N. F., Damm, J., Mathiesen, J. M., Ringholm, L., Damm, P., & Mathiesen, E. R. (2013) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2012.743523 · Cited by 50
Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study
IMBERGAMO, M., AMATO, M., SCIORTINO, G., GAMBINA, M., ACCIDENTI, M., CRISCIMANNA, A., GIORDANO, C., & GALLUZZO, A. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.013 · Cited by 46
Victor Fang, Y. M., Mackeen, D., Egan, J. F. X., & Zelop, C. M. (2009) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050802638170 · Cited by 45
González, C., Chico, A. I., Gich, I. J., & Corcoy, R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0032 · Cited by 45
Mortensen, L. H. (2012) · Social Science & Medicine · doi:10.1016/j.socscimed.2012.08.021 · Cited by 43
Is insulin lispro safe in pregnant women: does it cause any adverse outcomes on infants or mothers?
Aydın, Y., Berker, D., Direktör, N., Ustün, İ., Tütüncü, Y. A., Işık, S., Delibaşı, T., & Guler, S. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.02.004 · Cited by 36
Perinatal outcomes in pregnancies managed with antenatal insulin glargine
Egerman, R., Ramsey, R., Kao, L., Bringman, J., Haerian, H., Kao, J., & Bush, A. (2009) · American Journal of Perinatology · doi:10.1055/s-0029-1220782 · Cited by 35
Balaji, V., Balaji, M. S., Alexander, C., Srinivasan, A., Suganthi, S. R., Thiyagarajah, A., & Seshiah, V. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.650661 · Cited by 32
Magnitude of income-related disparities in adverse perinatal outcomes
Shankardass, K., O’Campo, P., Dodds, L., Fahey, J., Joseph, K., Morinis, J., & Allen, V. M. (2014) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-14-96 · Cited by 29
Fetal growth in relation to maternal and fetal IGF ‐axes: a systematic review and meta‐analysis
Elhddad, A. S., & Lashen, H. (2013) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.12192 · Cited by 27
Managing Diabetes During Pregnancy with Insulin Lispro: A Safe Alternative to Human Insulin
Edson, E. J., Bracco, O. L., Vambergue, A., & Koivisto, V. A. (2010) · Endocrine Practice · doi:10.4158/ep10003.ra · Cited by 27
Insulin glargine versus neutral protamine Hagedorn insulin for treatment of diabetes in pregnancy
Smith, J., Manuck, T., White, J., & Merrill, D. (2009) · American Journal of Perinatology · doi:10.1055/s-0028-1095181 · Cited by 22 · cited 1×
“3a) [16–19, 21, 22].”
Use of insulin lispro during pregnancy in women with pregestational diabetes mellitus
García-Domínguez, M., Herranz, L., Hillman, N., Martín-Vaquero, P., Jáñez, M., Chimenti, E. M., & Pallardo, L. F. (2011) · Medicina Clínica · doi:10.1016/j.medcli.2010.11.021 · Cited by 18
Colatrella, A., Visalli, N., Abbruzzese, S., Leotta, S., Bongiovanni, M., & Napoli, A. (2013) · International Journal of Endocrinology · doi:10.1155/2013/151975 · Cited by 15
Balaji, V., Balaji, M. S., Alexander, C., Ashalata, S., Suganthi, R. S., Suresh, S., & Seshiah, V. (2010) · PubMed · Cited by 12
Efficacy of insulin lispro in pregnancies complicated with pregestational diabetes mellitus
Banerjee, M., Bhattacharya, A., Hughes, S., & Vice, P. A. (2009) · Practical Diabetes · doi:10.1002/pdi.1423 · Cited by 8
Imbergamo, M. P., Amato, M. C., Amodeo, R., Magistro, A., Galluzzo, A., & Giordano, C. S. D. S. (2012) · CNR Solar (Scientific Open-access Literature Archive and Repository) (Consiglio Nazionale delle Ricerche) · Cited by 5
Research works printed but not linked: 1
- Edson EJ, Bracco OL, Vambergue A et al (2010) Managing diabetes during pregnancy with insulin lispro :a safe alternative to human insulin. Endocr Pract 16:1020–1027 · DOI
Cited by
ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002501 · Cited by 1,820
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Szmuilowicz, E. D., Josefson, J. L., & Metzger, B. E. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.05.001 · Cited by 364
Feig, D. S., Berger, H., Donovan, L., Godbout, A., Kader, T., Keely, E., & Sanghera, R. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.038 · Cited by 344
Practice Bulletin No. 180: gestational diabetes mellitus.
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002159 · Cited by 324
Metadata
- Authors
- Lv, S., Wang, J., & Xu, Y.
- Affiliations
- Southwest Medical University (CN)
- Corresponding author
- Xu, Yong
- ORCID
- Venue
- Archives of Gynecology and Obstetrics
- Published
- 2015-04-09
- Volume
- 292
- Issue
- 4
- Pages
- 749-756
- ISSN
- 0003-9128 (ISSN-L)
- 0932-0067
- 1432-0711
- OpenAlex
- W2048000124
- Cited by
- 88
- References
- 40
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 2 · 2023: 19 · 2022: 7 · 2021: 8 · 2020: 6 · 2019: 15 · 2018: 12 · 2017: 3 · 2016: 9 · 2015: 3
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Archives of Gynecology and Obstetrics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- insulin analogues, diabetes in pregnancy, gestational diabetes mellitus, pregestational diabetes, insulin aspart, insulin lispro, insulin glargine, insulin detemir, neonatal hypoglycemia, neonatal jaundice, birth weight, large for gestational age, macrosomia, cesarean section, neonatal intensive care admission, NPH insulin, regular insulin
- MeSH terms
- Insulin Glargine, Insulin Detemir, Adult, Birth Weight, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Infant, Newborn, Infant, Newborn, Diseases, Insulin, Pregnancy, Pregnancy in Diabetics, Pregnancy Outcome, Diabetes, Gestational, Insulin Aspart, Insulin Lispro
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.